Mirae Asset Global Investments Co., Ltd. Cullinan Oncology, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,280 shares of CGEM stock, worth $18,992. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,280
Previous 1,974
15.5%
Holding current value
$18,992
Previous $14,000
21.43%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.5MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$63.7 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$47.9 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$32.2 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$29.6 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$28.4 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $380M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...